Compounds > tram 39
Page last updated: 2024-11-11

tram 39

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(2-chlorophenyl)-2,2-diphenyl acetonitrile: an intermediate-conductance calcium-activated potassium channel blocker [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9861261
CHEMBL ID118687
SCHEMBL ID2392141
MeSH IDM0456419

Synonyms (13)

Synonym
CHEMBL118687
SCHEMBL2392141
2-chloro-?,?-diphenylbenzeneacetonitrile
197525-99-8
tram 39
AKOS024458432
tram-39
2-(2-chlorophenyl)-2,2-diphenylacetonitrile
2-(2-chlorophenyl)-2,2-diphenyl acetonitrile
tram39
2-chloro-alpha,alpha-diphenylbenzeneacetonitrile
CS-0027572
HY-103308
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID143824Mitogen-induced cell proliferation assay to evaluate the antiproliferative effect in NIH 3T3 cells2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Triaryl methane derivatives as antiproliferative agents.
AID143835Percent inhibition at 10 uM determined against mouse NIH 3T3 cells2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Triaryl methane derivatives as antiproliferative agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.01 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index69.20 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4-aminopyridine
[no description available]		2.0110aminopyridine;
aromatic amine		avicide;
orphan drug;
potassium channel blocker
clotrimazole
[no description available]		2.0210conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
hydroxyproline
Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.		2.01104-hydroxyproline;
L-alpha-amino acid zwitterion		human metabolite;
mouse metabolite;
plant metabolite
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		2.0110acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
substance p
[no description available]		2.0210peptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent
1-ethyl-2-benzimidazolinone
1-ethyl-2-benzimidazolinone: structure in first source		2.4220imidazoles
bradykinin
[no description available]		2.0210oligopeptidehuman blood serum metabolite;
vasodilator agent
8,11,14-eicosatrienoic acid
8,11,14-Eicosatrienoic Acid: A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.. all-cis-icosa-8,11,14-trienoic acid : An icosatrienoic acid having three cis double bonds at positions 8, 11 and 14.		2.0210fatty acid 20:3;
long-chain fatty acid		fungal metabolite;
human metabolite;
nutraceutical
bleomycetin
bleomycetin: RN given refers to parent cpd		2.0110
iberiotoxin
[no description available]		2.0210
charybdotoxin
[no description available]		2.0110
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0110
Experimental Lung Inflammation
Inflammation of any part, segment or lobe, of the lung parenchyma.		02.0110
Alveolitis, Fibrosing
[description not available]		02.0110
Pneumonia
Infection of the lung often accompanied by inflammation.		02.0110
Pulmonary Fibrosis
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.		02.0110
Diabetes Mellitus, Adult-Onset
[description not available]		02.0310
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.0310